These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26319536)

  • 1. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: are they equivalent?
    Kaplan NM
    J Am Soc Hypertens; 2015 Aug; 9(8):582-3. PubMed ID: 26319536
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
    Kanorskiĭ SG
    Kardiologiia; 2013; 53(10):89-95. PubMed ID: 24645559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Walczewska J; Siga O; Dzieza-Grudnik A; Krolczyk J; Wizner B; Wolkow PP; Borys A; Kolton-Wroz M; Gryglewska B; Grodzicki T
    J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31443094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on prevention of stroke: Which one is better?
    Xiao L; Ouyang H; Su Q; Huang Y
    Int J Cardiol; 2016 Nov; 223():56-57. PubMed ID: 27532235
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: observations from Val-HeFT and CALM.
    Chin BS; Lip GY
    J Hum Hypertens; 2001 Feb; 15(2):89-92. PubMed ID: 11317186
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker use and renal outcomes-reply.
    Hsu CC; Liu JS; Tarng DC
    JAMA Intern Med; 2014 Oct; 174(10):1706-7. PubMed ID: 25285739
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual renin-angiotensin system blockade and outcome benefits in hypertension: a narrative review.
    Mann JF; Böhm M
    Curr Opin Cardiol; 2015 Jul; 30(4):373-7. PubMed ID: 26049384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW
    South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract]   [Full Text] [Related]  

  • 13. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.
    Makani H; Bangalore S; Romero J; Wever-Pinzon O; Messerli FH
    Am J Med; 2011 Feb; 124(2):128-35. PubMed ID: 21295192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin inhibition: what are the clinical perspectives?
    Hollenberg NK
    Semin Nephrol; 2007 Sep; 27(5):511-8. PubMed ID: 17868787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do angiotensin II receptor antagonists affect blood pressure?
    de Leeuw PW
    Am J Cardiol; 1999 Jul; 84(2A):5K-6K. PubMed ID: 10437737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activation during exercise is not attenuated by inhibition of the renin angiotensin system: the role of physical activity.
    Kahan T; Schwieler JH; Wallén H; Nussberger J; Hjemdahl P
    J Hypertens; 2013 Oct; 31(10):2103-4. PubMed ID: 24107740
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity.
    Petidis K; Grammatiki M; Doumas M
    J Hypertens; 2013 Oct; 31(10):2103. PubMed ID: 24107739
    [No Abstract]   [Full Text] [Related]  

  • 19. Renoprotective effects of renin-angiotensin-system inhibitors.
    Mann JF; Ritz E; Kunz R
    Lancet; 2006 Mar; 367(9514):900; author reply 900-2. PubMed ID: 16546535
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
    Mancia G
    Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.